Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics and Pharmacodynamics of Finasteride

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Finasteride is a potent 5α-reductase inhibitor that has shown limited success in men treated for benign prostatic hyperplasia (success is defined as a decrease in the symptoms associated with urinary tract obstruction, and as increases in the urinary flow rate). 5α-reductase is necessary for the prostatic conversion of testosterone to dihydrotesterone (DHT), the specific steroid that stimulates prostate transitional zone growth. Finasteride reduces the size of the prostate gland by 20%, but this does not correlate well with improvement in symptoms.

Finasteride is well absorbed after oral administration and, while the rate of absorption may be slowed postprandially, the presence of food has no effect on the total bioavailability. Finasteride is widely distributed, but since its pharmacological effects are very specific to inhibition of 5α-reductase, and since only the prostate gland, the scalp, and the genital skin contain high concentrations of this enzyme, few adverse reactions will be seen in other organ systems.

Finasteride undergoes extensive hepatic metabolism to essentially inactive metabolites, which are eliminated through the bile and urine. The terminal elimination half-life (t00BDZ) is 4.7 to 7.1 hours; but despite this, slow accumulation occurs with multiple doses. Values of t00BDZ are higher in elderly men, but no dosage adjustments are necessary. Likewise, no dosage adjustments are necessary for patients with renal dysfunction, since the metabolites which accumulate are relatively inactive and well tolerated, and because greater faecal excretion of the metabolites occurs in these patients. The effect of hepatic dysfunction on the metabolism of finasteride is unknown.

Therapeutic doses of finasteride produce a rapid and pronounced effect in reducing both plasma and prostate tissue levels of DHT. Doses below 0.5 mg/day do not produce much suppression of DHT levels, and doses above 5 mg/day have little additional benefit. A single dose of finasteride suppresses serum DHT levels for up to 4 days, longer than would be expected from the serum terminal elimination half-life (t00BDZ) of the drug: this is probably due to the high affinity that finasteride has for the 5α-reductase enzyme. Serum testosterone levels increase in patients receiving finasteride, but are not normally outside the upper limits of the normal range. Serum prostate-specific antigen (PSA) levels decrease with finasteride administration; the baseline for investigation of prostate cancer with elevated PSA levels should be one-half of the normal range.

In responders to finasteride, the prostate gland shrinks in volume by about 20%, urinary flow rate improves by approximately 3 ml/s, and symptoms are relieved. The response to finasteride appears to be maximal at doses of 5 mg/day. For most men receiving finasteride, these effects will persist for at least the 5 years that long term studies have been conducted. Serum DHT levels increase again when finasteride therapy is discontinued, probably resulting in the return of the hyperplasia, decreased urine flow and obstructive symptoms.

Finasteride is well tolerated, with loss of libido and sexual potency being the most commonly reported adverse reactions. No drug interactions with finasteride have been reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Steiner JF. Finasteride: a 5α-reductase inhibitor. Clin Pharm 1993; 12: 15–23

    PubMed  CAS  Google Scholar 

  2. Proscar package insert, containing prescribing information. Rahway (NJ): Merck & Co., Inc., Dec 1994

  3. Merck Index. 11th ed. Rahway (NJ): Merck & Co, 1989: 1250

  4. Carlin JR, Christofalo P, Vandenheuvel WJA. High-performance liquid chromatographic determination of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxyamide, a 4-azasteroid in human plasma from a phase I study. J Chromatogr 1988; 427: 79–91

    Article  PubMed  CAS  Google Scholar 

  5. Constanzer ML, Matuszewski BK, Bayne WF. High-performance liquid Chromatographic method for the determination of finasteride in human plasma at therapeutic doses. J Chromatogr 1991; 566: 127–34

    Article  PubMed  CAS  Google Scholar 

  6. Constanzer ML, Chavez CM, Matuszewski BK. Picogram determination of finasteride in human plasma and semen by high-performance liquid chromatography with atmosphericpressure chemical-ionization tandem mass spectrometry. J Chromatogr B Biomed Appl 1994; 658: 281–7

    Article  PubMed  CAS  Google Scholar 

  7. Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991; 16: 15–21

    Article  PubMed  CAS  Google Scholar 

  8. Shimazaki J, Nose J. Phase I studies on MK-906, a 5α-reductase inhibitor: single dose (including food interaction) and multiple dose studies in healthy male volunteers. Yakuri To Chiryo 1990; 18(17): 2675–94

    CAS  Google Scholar 

  9. Winchell GA, Gregoire S, Constanzer ML, et al. Pharmacokinetics and oral bioavailability of the 5α-reductase inhibitor finasteride in man [abstract]. Pharmacol Res 1990; 7: S251

    Article  Google Scholar 

  10. Carlin JR, Höglund P, Eriksson L-O, et al. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos 1992; 20: 148–55

    PubMed  CAS  Google Scholar 

  11. Peters DH, Sorkin EM. Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993; 46: 177–208

    Article  PubMed  CAS  Google Scholar 

  12. De Schepper PJ, Imperato-McGinley J, VanHecken A, et al. Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5α-reductase inhibitor. Steroids 1991; 56: 469–71

    Article  PubMed  Google Scholar 

  13. Gregoire S, Winchell GA, Constanzer M, et al. Multiple dose pharmacokinetics of finasteride, a 5α-reductase inhibitor in men 45–60 and ≥70 years old [abstract]. Pharmacol Res 1990; 7: S53

    Google Scholar 

  14. Gregoire S, Winchell G, Constanzer M, et al. The effect of renal function on the disposition of finasteride, a new testosterone [abstract]. J Clin Pharmacol 1991; 31: 859

    Google Scholar 

  15. Stoner E. The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Molec Biol 1990; 37: 375–8

    Article  PubMed  CAS  Google Scholar 

  16. Ko HC, Jusko WJ. Pharmacodynamic modeling of finasteride, a 5α-reductase inhibitor. Pharmacotherapy 1995; 15: 509–11

    PubMed  CAS  Google Scholar 

  17. Cunningham GR, Hirshkowitz M. Inhibition of steroid 5α-reductase with finasteride: sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab 1995; 80: 1934–40

    Article  PubMed  CAS  Google Scholar 

  18. Weisser H, Tunn S, Debus M, et al. 5α-reductase inhibition by finasteride (Proscar®) in epithelium and stroma of human benign prostatic hyperplasia. Steroids 1994; 59: 616–20

    Article  PubMed  CAS  Google Scholar 

  19. Krieg M, Weisser H, Tunn S. Potential activities of androgen metabolizing enzymes in human prostate. J Steroid Biochem Mol Biol 1995; 53: 395–400

    Article  PubMed  CAS  Google Scholar 

  20. Rittmaster RS, Stoner E, Thompson DL, et al. Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 1989; 10: 259–62

    PubMed  CAS  Google Scholar 

  21. Vermeulen A, Giagulli VA, De Shapper P, et al. Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in humans. Prostate 1989; 14: 45–53

    Article  PubMed  CAS  Google Scholar 

  22. Gromley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5-alpha reductase inhibitor on circulating androgens in male volunteers. J Clin Endocrinol Metabol 1990; 70: 1136–41

    Article  Google Scholar 

  23. Grino P, Stoner E, the Finasteride Study Group. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. Eur Urol 1994; 25 Suppl. 1: 24–8

    PubMed  Google Scholar 

  24. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–91

    Article  PubMed  CAS  Google Scholar 

  25. Geller J. Effect of finasteride, a 5α-reductase inhibitor, on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990; 71: 1552–5

    Article  PubMed  CAS  Google Scholar 

  26. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505–8

    Article  PubMed  CAS  Google Scholar 

  27. Norman RW, Coakes KE, Wright AS, et al. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 1993; 150: 1736–9

    PubMed  CAS  Google Scholar 

  28. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31–7

    Article  PubMed  CAS  Google Scholar 

  29. Guess HA, Heyse JF, Gormley GJ, et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Urol Clin North Am 1993; 20: 627–36

    PubMed  CAS  Google Scholar 

  30. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31–7

    Article  PubMed  CAS  Google Scholar 

  31. Andriole GL. Finasteride-induced PSA reductions in patients with early-stage prostate cancer [abstract]. J Urol 1994; 151 Suppl.: 450A

    Google Scholar 

  32. Matzkin H, Chen J, Lewyshon O, et al. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol. Horm Metab Res 1992; 24: 498–9

    Article  PubMed  CAS  Google Scholar 

  33. Rittmaster RS, Antonian L, New MI, et al. Effect of finasteride on adrenal steroidogenesis in men. J Androl 1994; 15: 298–301

    PubMed  CAS  Google Scholar 

  34. Jaffe A, Matzkin H, Gilad S, et al. Effect of 5-alpha reductase inhibition on sex-hormone-binding globulin in elderly men. Horm Res 1994; 41: 215–7

    Article  PubMed  CAS  Google Scholar 

  35. MK-906 (Finasteride) Study Group. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. J Androl 1991; 12: 372–5

    Google Scholar 

  36. Nancey JN, Meffan PJ, Delahunt B. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia. Aust NZ J Surg 1995; 65: 35–9

    Article  Google Scholar 

  37. Volpi R, Macccarini PA, Boni S, et al. Case report: finasteride-induced gynecomastia in a 62-year-old man. Am J Med Sci 1995; 309: 322–5

    Article  PubMed  CAS  Google Scholar 

  38. Faller B, Farley D, Mick H. Finasteride: a slow-binding 5α-reductase inhibitor. Biochemistry 1993; 32: 5705–10

    Article  PubMed  CAS  Google Scholar 

  39. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321: 303–9

    Article  PubMed  CAS  Google Scholar 

  40. Walsch PC. Benign prostatic hyperplasia. In: Walsch PC, Retick AB, Stamey TA, et al., editors. Campbell’s Urology. 6th ed. Philadelphia: Saunders, 1992: 1009–27

    Google Scholar 

  41. Stoner E, Finasteride Study Group. The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol 1992; 147: 1298–302

    PubMed  CAS  Google Scholar 

  42. Beisland HO, Bindowitz B, Brekkan E, et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992; 22: 271–7

    PubMed  CAS  Google Scholar 

  43. Tammela TLJ, Kontturi MJ. Urodynanamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol 1993; 149: 342–4

    PubMed  CAS  Google Scholar 

  44. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291–9

    Article  Google Scholar 

  45. Lepor H. Editorial comment on: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 292–3

    Google Scholar 

  46. Stoner E, Finasteride Study Group. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch Intern Med 1994; 154: 83–8

    Article  PubMed  CAS  Google Scholar 

  47. Stoner E, Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284–92

    Article  PubMed  CAS  Google Scholar 

  48. Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol 1995; 27: 267–73

    PubMed  CAS  Google Scholar 

  49. Tewari A, Shinohara K, Narayn P. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology 1995; 45: 258–65

    Article  PubMed  CAS  Google Scholar 

  50. Winchell GA, Gregoire S, Taylor AM, et al. Finasteride, a steroid 5α-reductase inhibitor, does not affect the oxidative metabolism of antipyrine. J Clin Pharmacol. 1993; 33: 967–70

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Family Practice Residency Program, University of Wyoming, 1522 East A Street, Casper, Wyoming, 82071, USA

    Joseph F. Steiner

Authors
  1. Joseph F. Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steiner, J.F. Clinical Pharmacokinetics and Pharmacodynamics of Finasteride. Clin-Pharmacokinet 30, 16–27 (1996). https://doi.org/10.2165/00003088-199630010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199630010-00002

Keywords

Search

Navigation